Localized prostate tumors have various clinical, biological and histopathological characteristics that lead to different progression profiles.
High-risk prostate cancer has been classically defined by clinical examination, PSA levels and histopathological data. High-risk prostate cancer has usually a worse outcome, but classic stratification predictive of outcome for prostate cancer is a matter of debate concerning its accuracy. A great deal of scientific work have been deploy to prove that high-risk prostate cancer should be approached by teamwork including radio-hormone therapy, systemic treatment with long-term use of LH-RH and a radical prostatectomy with adequate lymph node dissection. Selection of patients is essential to define individualized therapeutic strategy and timing for every modality should come as a consensus of medical supported evidence. Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer.
Written by:
Rozet F. Are you the author?
Université Paris-Descartes, 75014 Paris, France.
Reference: Rev Prat. 2013 Apr;63(4):494-6.
PubMed Abstract
PMID: 23682476
Article in French.
UroToday.com Prostate Cancer Section
